Long-term efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis who had failed or were intolerant to oral nonsteroidal immunosuppressants: pooled analysis of JADE clinical trials

被引：0
|
作者：
Ardern-Jones, M. [1 ]
Ameen, M. [2 ]
de Bruin-Weller, M. [3 ]
Simpson, E. [4 ]
Chiu, W. S. [5 ]
Biswas, P. [6 ]
Chan, G. [7 ]
Koulias, C. [8 ]
Weidinger, S. [9 ]
机构：
[1] Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England
[2] Royal Free London Natl Hlth Serv Fdn Trust, London, England
[3] Univ Med Ctr Utrecht, Utrecht, Netherlands
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Pfizer Ltd, Surrey, England
[6] Pfizer Inc, New York, NY USA
[7] Pfizer Inc, Groton, CT 06340 USA
[8] Pfizer Hellas SA, Athens, Greece
[9] Univ Hosp Schleswig Holstein, Kiel, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
642
引用
收藏
页码：E151 / E152
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials
    Gooderham, Melinda J.
    Ardern-Jones, Michael R.
    Guttman-Yassky, Emma
    Ameen, Mahreen
    Simpson, Eric L.
    Chan, Gary
    Biswas, Pinaki
    Chiu, Wing S.
    Watkins, Melissa
    JEADV CLINICAL PRACTICE, 2023, 2 (04): : 753 - 763
  • [2] Efficacy of abrocitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis who had an inadequate response or intolerance to nonsteroidal immunosuppressants: results from JADE DARE
    Ardern-Jones, Michael
    Ameen, Mahreen
    de Bruin-Weller, Marjolein
    Simpson, Eric
    Chiu, Wing Sin
    Zhang, Fan
    Chan, Gary
    Koulias, Christopher
    Weidinger, Stephan
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 71 - 72
  • [3] Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND
    Paller, Amy S.
    Cork, Michael J.
    Flohr, Carsten
    Bangert, Christine
    Weidinger, Stephan
    Nesnas, John
    Farooqui, Saleem A.
    Biswas, Pinaki
    Watkins, Melissa
    Koppensteiner, Herwig
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [4] Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial program
    Eichenfield, Lawrence F.
    Flohr, Carsten
    Bangert, Christine
    Irvine, Alan D.
    Weidinger, Stephan
    Nesnas, John
    Koppensteiner, Herwig
    Zhang, Fan
    Rojo, Ricardo
    Chan, Gary
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [5] Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial programme
    Eichenfield, L. F.
    Flohr, C.
    Bangert, C.
    Irvine, A. D.
    Weidinger, S.
    Nesnas, J.
    Koppensteiner, H.
    Zhang, F.
    Rojo, R.
    Chan, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E142 - E143
  • [6] Abrocitinib Long-Term Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
    Reich, Kristian
    Silverberg, Jonathan I.
    de Bruin-Weller, Marjolein
    Deleuran, Mette
    Beck, Lisa A.
    Papp, Kim
    Farooqui, Saleem A.
    Zhang, Fan
    Feeney, Claire
    Koppensteiner, Herwig
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB116 - AB116
  • [7] Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Gooderham, Melinda
    Chan, Gary
    Feeney, Claire
    Biswas, Pinaki
    Valdez, Hernan
    DiBonaventura, Marco
    Nduaka, Chudy
    Rojo, Ricardo
    JAMA DERMATOLOGY, 2020, 156 (08) : 863 - 873
  • [8] Efficacy and safety of abrocitinib in adolescent patients with moderate-to-severe atopic dermatitis: stratified analysis across three clinical trials
    Simpson, E.
    Lio, P.
    Heath, C.
    Boguniewicz, M.
    Levenberg, M.
    Biswas, P.
    Farooqui, S.
    Kerkmann, U.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E140 - E140
  • [9] Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials
    Meher, Bikash Ranjan
    Mohanty, Rashmi Ranjan
    Padhy, Biswa Mohan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2335 - 2343
  • [10] Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
    Gooderham, Melinda J.
    Weidinger, Stephan
    Simpson, Eric L.
    Deleuran, Mette
    Gold, Linda F. Stein
    Farooqui, Saleem A.
    Biswas, Pinaki
    Chan, Gary
    Guler, Erman
    Koppensteiner, Herwig
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II32 - II33
12345